Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant dangers » significant changes (Expand Search), significant advances (Expand Search), significant barriers (Expand Search)
dangers decrease » larger decrease (Expand Search), largest decrease (Expand Search)
Showing 2,241 - 2,260 results of 21,342 for search '(( significant dangers decrease ) OR ( significant decrease decrease ))', query time: 0.40s Refine Results
  1. 2241
    Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant.

    Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant. by Aga E. Gelgie (17661720)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 2242
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 2243
    Flowchart of the exclusive breastfeeding mothers (EBF) and the exclusive breastfeeding mother-donors (EBF+) who participated in the study.

    Flowchart of the exclusive breastfeeding mothers (EBF) and the exclusive breastfeeding mother-donors (EBF+) who participated in the study. by Larissa Brazolotto Ferreira (17671168)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 2244
    Timeline of monitoring of exclusive breastfeeding mothers (EBF) and exclusive breastfeeding – donors (EBF+).

    Timeline of monitoring of exclusive breastfeeding mothers (EBF) and exclusive breastfeeding – donors (EBF+). by Larissa Brazolotto Ferreira (17671168)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 2245
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 2246
    Study-related adverse events.

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 2247
    <i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces.

    <i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces. by Aga E. Gelgie (17661720)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 2248
    Data supporting the findings of this study.

    Data supporting the findings of this study. by Aga E. Gelgie (17661720)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 2249
    Comparison of densitometric, biochemical, and hormonal variables, and bone turnover markers of EBF + 6 months versus EBF + one year postpartum.

    Comparison of densitometric, biochemical, and hormonal variables, and bone turnover markers of EBF + 6 months versus EBF + one year postpartum. by Larissa Brazolotto Ferreira (17671168)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 2250
    Study flow chart.

    Study flow chart. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 2251
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 2252
    I Optimal design for optimization of Axitinib loaded Spanlastics.

    I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 2253
    Study CONSORT diagram.

    Study CONSORT diagram. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 2254
    ANOVA for I optimal design of Axitinib loaded Spanlastics.

    ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 2255
    The kinetic release data of the optimized formula compared to drug suspension.

    The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 2256
    Change in Demoralization Scale (DSII) by Treatment Group.

    Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 2257
    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group.

    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 2258
    Oligonucleotides used in this study.

    Oligonucleotides used in this study. by Aga E. Gelgie (17661720)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 2259
    Open data.

    Open data. by Larissa Brazolotto Ferreira (17671168)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 2260
    Impact of 5′ nucleotidase disruption on <i>M</i>. <i>bovis</i> growth phenotype in axenic conditions.

    Impact of 5′ nucleotidase disruption on <i>M</i>. <i>bovis</i> growth phenotype in axenic conditions. by Aga E. Gelgie (17661720)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: